Roche, Zur Rose Group Start Program For Diabetics

Roche, a leader in integrated personalized diabetes management, and the Zur Rose Group, provider of a European digital healthcare ecosystem, have agreed to collaborate in improving therapy management and better address the needs of 60 million people living with diabetes in Europe.

Photo Insert: The Roche-Zur Rose collaboration will empower people with diabetes to self-manage their condition and enable healthcare professionals to efficiently provide optimal and integrated care.

The collaboration will empower people with diabetes to self-manage their condition and enable healthcare professionals to efficiently provide optimal and integrated care, Deutsche Presse-Agentur (dpa) reported.

Roche and the Zur Rose Group today announced a collaboration to empower people with diabetes and their caregivers in their daily therapy. The 60 million people living with diabetes in Europe represent approximately 9% of the population older than 20 years.

The prevalence of diabetes is rising among all ages and in particular of type-2 diabetes, which is mostly due to decreases in physical activity and an unhealthy diet. It is becoming one of the major healthcare issues for society across the globe.

As part of the collaboration, Roche Diabetes Care and the Zur Rose Group are connecting their healthcare products and solutions and those of best-in-class third parties to improve the lives of people with diabetes.

This offering will become available in Germany as a first market in 2022 and is foreseen to be expanded to other European markets. It will focus primarily on people living with type 2 diabetes, which accounts for about 90% of all cases.

WEEKLY FEATURE : MVP Group Keeps Lights On During Pandemic